Meanwhile, there were four MEN1 patients who received Lanreotide or Octreotide therapy due to gastrointestinal and/or pancreatic NETs and one acromegaly patient with excluded MEN1 syndrome by genetic testing, who was treated by Lanreotide due to pituitary disease persistence after transsphenoidal surgery. This evidence concerns the gene MEN1 and pituitary gland disorder.